Evaluation of lipoprotein (a) [Lp(a)] and lipid abnormalities in patients with newly detected hypertension and its association with severity of hypertension
- PMID: 35516713
- PMCID: PMC9067179
- DOI: 10.4103/jfmpc.jfmpc_989_21
Evaluation of lipoprotein (a) [Lp(a)] and lipid abnormalities in patients with newly detected hypertension and its association with severity of hypertension
Abstract
Introduction: Hypertension remains the major preventable cause of cardiovascular disease (CVD). Lipoprotein (a) is seen to be associated with established essential hypertension and contributes to atherogenesis or to thrombogenesis or both.
Aim: Correlation between lipoprotein (a) [Lp(a)] and lipid abnormalities in patients with newly detected hypertension and its association with severity of hypertension.
Methods: It was a cross-sectional observational study carried out at PGIMER, DR. RML Hospital, New Delhi, India. Estimation of serum Lp (a) and lipid parameters along with routine laboratory investigations were carried out in 100 newly diagnosed cases with hypertension and compared with age and sex matched 50 healthy normotensive controls.
Result: Amongst 100 cases the mean systolic and diastolic blood pressure was 160.68 ± 19.75 mmHg and 84.44 ± 4.32 mmHg respectively. The mean serum Lp (a) in cases was 34.03 ± 7.55 mg/dl as compared to 24.13 ± 4.41 mg/dl in controls (p < 0.0001). 62% of cases as compared to 12% of controls had elevated serum Lp (a) levels. Apart from that, the levels of Lp (a) and lipid parameters increased significantly with higher stage of disease (p < 0.0001). Approximately 8% of cases had left ventricular hypertrophy as compared to 1% of control. Similarly, 18% of cases had Non-alcoholic fatty liver disease as compared to 4% of controls. 5% of cases had retinopathy as compared to nil in controls. 4% of cases had microalbuminuria as compared to nil in controls.
Conclusion: It was observed that newly detected hypertension is associated with major derangements of Lp (a) and lipid parameters. We also concluded that end organ involvement is significantly higher in newly detected hypertensives as compared to normotensive subjects and it was attributed to be due to lipid abnormalities observed in the group.
Keywords: Grading of hypertension; lipid profile; lipoprotein (a); newly detected hypertension.
Copyright: © 2022 Journal of Family Medicine and Primary Care.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Lipoprotein (a), C-reactive protein and some metabolic cardiovascular risk factors in type 2 DM.Diabetol Metab Syndr. 2010 Jul 27;2:51. doi: 10.1186/1758-5996-2-51. Diabetol Metab Syndr. 2010. PMID: 20663222 Free PMC article.
-
Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension.JAMA. 1997 Jun 4;277(21):1689-95. JAMA. 1997. PMID: 9169895
-
Relationship between Lipoprotein(a) and Thyroid Hormones in Hypothyroid Patients.J Clin Diagn Res. 2014 Feb;8(2):37-9. doi: 10.7860/JCDR/2014/7817.4001. Epub 2014 Feb 3. J Clin Diagn Res. 2014. PMID: 24701476 Free PMC article.
-
Lipoprotein -- an independent risk factor for CVD.Mymensingh Med J. 2005 Jul;14(2):136-40. Mymensingh Med J. 2005. PMID: 16056198
-
Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor.Atherosclerosis. 2020 Apr;299:32-37. doi: 10.1016/j.atherosclerosis.2020.02.026. Epub 2020 Mar 7. Atherosclerosis. 2020. PMID: 32203743
Cited by
-
Lipoprotein(a): Just an Innocent Bystander in Arterial Hypertension?Int J Mol Sci. 2023 Aug 29;24(17):13363. doi: 10.3390/ijms241713363. Int J Mol Sci. 2023. PMID: 37686169 Free PMC article. Review.
References
-
- Gupta R, Gaur K, Venkata S, Ram C. Emerging trends in hypertension epidemiology in India. J Hum Hypertens. 2019;33:575–87. - PubMed
-
- Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. PURE Study Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959–68. - PubMed
-
- Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mmHg, 1990-2015. JAMA. 2017;317:165–82. - PubMed
-
- Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death:A systematic review and meta-analysis. Lancet. 2016;387:957–67. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous